Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic
More Lipids For COVID-19 Vaccines
Executive Summary
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.